Zealand Pharma A-S Aktie [WKN DE: A0YJW7 / ISIN: DK0060257814]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Zealand Pharma A-S

11.11.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
07.11.24		Zealand Pharma Announces Financial Results for the First Nine Months of 2024 (GlobeNewswire)
09.10.24		Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism (GlobeNewswire)
08.10.24		Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide (GlobeNewswire)
30.09.24		Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 (GlobeNewswire)
12.09.24		Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
09.09.24		Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide (GlobeNewswire)
30.08.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
30.08.24		Total number of shares and voting rights in Zealand Pharma on August 30, 2024 (GlobeNewswire)
22.08.24		Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
16.08.24		Zealand Pharma major shareholder announcement: Bank of America Corporation (GlobeNewswire)
15.08.24		Zealand Pharma Announces Financial Results for the First Half of 2024 (GlobeNewswire)
28.06.24		Zealand Pharma major shareholder announcement: Van Herk Investments (GlobeNewswire)
28.06.24		Total number of shares and voting rights in Zealand Pharma at June 28, 2024 (GlobeNewswire)
28.06.24		Zealand Pharma completes registration of capital increase (GlobeNewswire)
26.06.24		Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion (GlobeNewswire)
25.06.24		Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion (GlobeNewswire)
25.06.24		Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion (GlobeNewswire)
20.06.24		Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide (GlobeNewswire)
13.06.24		Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
07.06.24		Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis (GlobeNewswire)
06.06.24		Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL (GlobeNewswire)
29.05.24		Zealand Pharma major shareholder announcement: Polar Capital (GlobeNewswire)
23.05.24		Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide (GlobeNewswire)
16.05.24		Zealand Pharma Announces Financial Results for the First Quarter of 2024 (GlobeNewswire)
12.05.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
19.04.24		Correction to Company announcement – No. 23 / 2024 (GlobeNewswire)
19.04.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
19.04.24		Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 (GlobeNewswire)
31.03.24		Total number of shares and voting rights in Zealand Pharma at March 31, 2024 (GlobeNewswire)
26.03.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
26.03.24		Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
21.03.24		Zealand Pharma major shareholder announcement: Van Herk Investments (GlobeNewswire)
20.03.24		Zealand Pharma's Annual General Meeting 2024 (GlobeNewswire)
19.03.24		Zealand Pharma major shareholder announcement: Polar Capital (GlobeNewswire)
19.03.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
13.03.24		New Employee Elected Directors to the Board of Zealand Pharma A/S (GlobeNewswire)
08.03.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
05.03.24		Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (GlobeNewswire)
05.03.24		Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants (GlobeNewswire)
27.02.24		Zealand Pharma convenes its Annual General Meeting 2024 (GlobeNewswire)
27.02.24		Zealand Pharma Announces Financial Results for the Full Year 2023 (GlobeNewswire)
26.02.24		Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibro (GlobeNewswire)
31.01.24		Total number of shares and voting rights in Zealand Pharma at January 31, 2024 (GlobeNewswire)
26.01.24		Zealand Pharma major shareholder announcement: Van Herk Investments (GlobeNewswire)
19.01.24		Zealand Pharma major shareholder announcement: J O Hambro Capital Management (GlobeNewswire)
17.01.24		Zealand Pharma major shareholder announcement: J O Hambro Capital Management (GlobeNewswire)
12.01.24		Zealand Pharma completes registration of capital increase (GlobeNewswire)
10.01.24		Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC (GlobeNewswire)
08.01.24		Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion (GlobeNewswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

NVIDIA vor Q3-Ergebnissen: Hohe Erwartungen und höhere Kursziele für den KI-Giganten

Ripple explodiert – Jetzt investieren und Millionär werden?

Diese Aktien befinden sich Q3 2024 im Portfolio von Warren Buffett

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

thyssenkrupp-Aktie zieht dennoch an: thyssenkrupp mit weiterem Milliardenverlust

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	21.11.2024 23:01
Kaufwert:	EUR
	Hinzufügen Speichern